ClinicalTrials.gg
CompletedNCT04615403Updated Sep 26, 2023Results posted

Study of Exchange of Travoprost Intraocular Implant

A Phase 2 interventional study of Travoprost in Open Angle Glaucoma, sponsored by Glaukos Corporation. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Glaukos Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
42nd of 45
33 · median 135
Started
2020
the only one that year
Phase 2
6 of 46
none open now
Registered
42nd of 46
by date
Lead sponsor
7 of 46
Glaukos Corporation

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 42nd largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2020, is one of 6 in phase 2, and was the 42nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.

Read the detailed description

This prospective, non-randomized, open-label, multi-center, single arm, clinical trial intends to implant approximately 45 male and female subjects over 18 years old who have been diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT). All subjects are required to meet eligibility criteria at Visit 1 (Screening). The purpose of this study is to evaluate the safety of the implantation and exchange of a Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension. Postoperatively, there are 6 follow-up visits over a 12 month period.

03

Conditions studied

  • Open Angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to attend scheduled follow-up exams for the duration of the study
  • Able and willing to provide written on the IRB (institutional review board)/IEC (institutional ethics committee)-approved Informed Consent form
  • Best spectacle corrected visual acuity of 20/80 or better in each eye.
  • Previously qualified for GC-009 clinical trial using the Travoprost Intraocular Implant with the travoprost intraocular implant (G2TR) that is present in the study eye.

Exclusion criteria

Exclusion Criteria:

  • Glaucoma status as follows:

    • Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders
  • Corneal status as follows:

    • Any active inflammation or edema
  • Any pathology for which, in the investigator's judgement, the following would be either at risk or :
  • Implantation of Travoprost Intraocular Implant
  • Compliance to elements of the study protocol (e.g., ophthalmic examinations, follow-up visits)
  • Fellow eye status as follows:

    • Fellow eye actively enrolled in this trial or any other clinical trial
  • Subject status as follows:

    • Pregnant or planning to become pregnant during the course of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Implantation and Exchange

    Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.

    Drug: Travoprost

Interventions

  • Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision

06

What researchers measure

Primary outcomes

  1. Ocular Safety

    Number of subjects with Adverse Events including intra-operative and post-operative events (TEAE's) in the study eye

    Time frame: 12 Months

07

Results

Posted Sep 26, 2023
Limitations and caveats
This was a single arm, open label study in a small number of subjects to assess safety of administration of a second implant and removal of the previous implant.

Participant flow

Participant flow — Overall Study
MilestoneImplantation and Exchange
Started33
Completed32
Not completed1
Withdrew: Death1

Outcome measures

PrimaryOcular Safety

Number of subjects with Adverse Events including intra-operative and post-operative events (TEAE's) in the study eye

Time frame:
12 Months
Reported as:
Number · subjects
Ocular Safety
subjectsImplantation and Exchange
Ocular Safety13

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Implantation and Exchange1/33 (3%)2/33 (6.1%)16/33 (48.5%)
Most frequent serious events
Most frequent serious events
EventImplantation and Exchange
DeathGeneral disorders1/33
Retinal vein occlusionEye disorders1/33
Most frequent other events
Showing 10 of 18
Most frequent other events
EventImplantation and Exchange
Visual field defectNervous system disorders3/33
Eye irritationEye disorders2/33
Corona virus infectionInfections and infestations2/33
Intraocular pressure increasedInvestigations2/33
Corneal pigmentationEye disorders1/33
Diabetic retinopathyEye disorders1/33
IridodialysisEye disorders1/33
PhotophobiaEye disorders1/33
Posterior capsule opacificationEye disorders1/33
Retinal hemorrhageEye disorders1/33

Baseline characteristics

safety population (all participants who underwent the exchange procedure)

Age, Categorical
Age, Categorical(Participants)Implantation and Exchange
<=18 years0
Between 18 and 65 years15
>=65 years18
Age, Continuous
Age, Continuous(years)Implantation and Exchange
Mean65.2 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Implantation and Exchange
Female17
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Implantation and Exchange
Hispanic or Latino2
Not Hispanic or Latino31
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Implantation and Exchange
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American1
White28
More than one race0
Unknown or Not Reported1
Duration since initial implant administration
Duration since initial implant administration(days)Implantation and Exchange
Mean1540.8 ± 123.7
08

Study locations

14 sites
  • Inland Eye Specialists
    Hemet, California 92545, United States
  • North Bath Eye Associates, Inc.
    Petaluma, California 94954, United States
  • Eye Center of northern Colorado, PC
    Fort Collins, Colorado 80525, United States
  • The Eye Associates of Manatee
    Manatee, Florida 34209, United States
  • Ocala Eye
    Ocala, Florida 34471, United States
  • Center for Sight
    Sarasota, Florida 34239, United States
  • Jones Eye Clinic
    Sioux City, Iowa 51104, United States
  • D'Ambrosio Eye Care
    Lancaster, Massachusetts 01523, United States
  • Northern New Jersey Eye Institute
    South Orange, New Jersey 07079, United States
  • Oklahoma Eye Surgeons
    Oklahoma City, Oklahoma 73112, United States
  • Vance Thompson Vision
    Sioux Falls, South Dakota 57108, United States
  • Texan Eye
    Austin, Texas 78746, United States
  • Lehmann Eye Center
    Nacogdoches, Texas 75965, United States
  • Asian Eye Institute
    Makati City, Philippines
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Feb 2022, 15 months.

Results were first posted in Sep 2023, 1 year 6 months after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 15 months is above that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 4, 2020
StartActual
Nov 19, 2020
Primary completionActual
Feb 28, 2022
CompletionActual
Feb 28, 2022
Results first posted
Sep 26, 2023
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04615403
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Nov 19, 2020
Primary completion
Feb 28, 2022
Completion
Feb 28, 2022
Results posted
Sep 26, 2023
Last update
Sep 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion